German Real-World Registry shows meaningful and sustained weight loss for at least one year after a single Revita endoscopic procedure
FDA grants Breakthrough Device Designation for Fractyl’s Revita in weight maintenance for people with obesity who discontinue GLP-1s
Revita German Real-World Registry: First 14 participants continue to demonstrate sustained improvements in blood glucose and weight
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
Revita results in weight loss and sustained weight maintenance without weight regain at one year
Fractyl’s Revita DMR System commercially available in Germany
Fractyl Health reports latest Revita DMR outcomes for T2DM
Two-year Revita DMR outcomes show durability of procedure in diabetics
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
Revita DMR granted FDA Breakthrough Device Designation for T2DM
